Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -70.45% | -28.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -70.45% | -28.20% | |||
| Cost of Revenue | 76.30% | -75.26% | |||
| Gross Profit | -533.33% | 114.36% | |||
| SG&A Expenses | -16.22% | -48.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.77% | -67.59% | |||
| Operating Income | -291.02% | 86.23% | |||
| Income Before Tax | -38.64% | 61.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -38.64% | 61.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.64% | 61.81% | |||
| EBIT | -291.02% | 86.23% | |||
| EBITDA | -293.12% | 86.31% | |||
| EPS Basic | -37.38% | 62.90% | |||
| Normalized Basic EPS | -262.22% | 85.74% | |||
| EPS Diluted | -37.38% | 62.90% | |||
| Normalized Diluted EPS | -262.22% | 85.74% | |||
| Average Basic Shares Outstanding | 0.92% | 2.96% | |||
| Average Diluted Shares Outstanding | 0.92% | 2.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||